Ftse Mib
34.584,59
-0,51%
DAX
18.648,88
-0,60%
S&P 500
5.303,36
-0,03%
NASDAQ
0,00
0,00%
Bitcoin
67.861,13
-2,21%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Organon and Co (OGN) Organon and Co (OGN) Notizie

OGN

Organon (OGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:OGN
DataOraFonteTitoloSimboloCompagnia
24/05/202419:59Business WireL’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)NYSE:OGNOrganon and Co
24/05/202419:59Business WireEuropäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14NYSE:OGNOrganon and Co
24/05/202417:29Business Wire欧州医薬品庁（EMA）、ヘンリウスとオルガノンによるProlia ® およびXgeva ® （デノスマブ）バイオシミラー候補HLX14を認証NYSE:OGNOrganon and Co
24/05/202412:00Business WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14NYSE:OGNOrganon and Co
17/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
08/05/202402:20Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
07/05/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202413:58Business WireOrganon Announces Proposed $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
02/05/202413:30Business WireOrganon Reports Results for the First Quarter Ended March 31, 2024NYSE:OGNOrganon and Co
09/04/202414:13Business WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
08/04/202420:31Business WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
08/04/202420:31Business WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
08/04/202412:15Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
08/04/202412:00Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
08/03/202415:01PR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
08/03/202415:01PR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
26/02/202414:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:OGNOrganon and Co
20/02/202414:00Business WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National FormularyNYSE:OGNOrganon and Co
15/02/202413:30Business WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023NYSE:OGNOrganon and Co
01/02/202413:30Business WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024NYSE:OGNOrganon and Co
10/01/202413:33Business WireOrganon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and OlderNYSE:OGNOrganon and Co
08/01/202413:30Business WireOrganon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlookNYSE:OGNOrganon and Co
21/12/202313:30Business WireOrganon To Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
19/12/202314:30Business WireOrganon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraineNYSE:OGNOrganon and Co
19/12/202310:11Business WireOrganon と Lilly、ヨーロッパで 2 種類の片頭痛薬商業化契約を締結NYSE:OGNOrganon and Co
19/12/202303:26Business WireOrganon und Lilly schließen Vermarktungsvereinbarung für zwei Migräne-Medikamente in EuropaNYSE:OGNOrganon and Co
18/12/202313:30Business WireOrganon & Lilly Enter Commercialization Agreement in Europe for Two Migraine MedicinesNYSE:OGNOrganon and Co
21/11/202313:30Business WireOrganon To Present at the Piper Sandler 35th Annual Healthcare ConferenceNYSE:OGNOrganon and Co
07/11/202322:15GlobeNewswire Inc.Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®NYSE:OGNOrganon and Co
03/11/202312:52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:OGN

La tua Cronologia

BIT
SOROS5
Italian Stock Exchange
BIT
F17922
Vontobel Financial Produ...
AMEX
HUSA
Houston American Energy
USOTC
SCPJ
Scope Industries (CE)
NASDAQ
CCAIW
Cascadia Acquisition
ASX
WHF
Whitefield Industrials
BIT
UC0ZYL
Unicredit Bank
NASDAQ
IMMX
Immix Biopharma
COIN
IFXBTC
USOTC
BMDPF
Banca Monte Dei Paschi D... (PK)
COIN
MRYCUSD
HITB
FUNUSD
FunFair
BIT
UB2XSV
UniCredit Bank
BMF
SWIU24
SWIU24 - Setembro 2024
NASDAQ
GITWCX
GoalPath Fi360 2020 Inde...
TSX
ESP
Brompton Energy Split
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network